Monday, January 13, 2014

Anesthetic Management on a Patient with Friedreich’s Ataxia

›
Anesthetic Management on a Patient with Friedreich’s Ataxia . Ozgul U, Erdogan MA, Aydogan MS, Korkmaz MF, Nakir H, Durmus M.; Med-Science. ...

Role of Frataxin and Mitochondrial Dysfunction in Friedreich's Ataxia

›
Giovanni Manfredi, MD, PhD, Professor of Neurology and Neuroscience, Weill Medical College of Cornell University

Role of Frataxin and Mitochondrial Dysfunction in Friedreich's Ataxia

›
Giovanni Manfredi, MD, PhD, Professor of Neurology and Neuroscience, Weill Medical College of Cornell University
Saturday, January 11, 2014

Occurrence of adverse events in chronic intrathecal baclofen infusion: a one-year follow-up study of 158 adults

›
Occurrence of adverse events in chronic intrathecal baclofen infusion: a one-year follow-up study of 158 adults . Léo Borrini, Djamel Bensma...

MITOCHONDRIA: Mitochondrial OXPHOS (dys) function ex-vivo - the use of primary fibroblasts

›
MITOCHONDRIA: Mitochondrial OXPHOS (dys) function ex-vivo - the use of primary fibroblasts . Ann Saada, The International Journal of Biochem...
Monday, January 6, 2014

The kinetics of folding of frataxin

›
The kinetics of folding of frataxin . Daniela Bonetti, Angelo Toto, Rajanish Giri, Angela Morrone, Domenico Sanfelice, Annalisa Pastore, PA ...
Sunday, January 5, 2014

HFE p.C282Y heterozygosity is associated with earlier disease onset in Friedreich ataxia

›
HFE p.C282Y heterozygosity is associated with earlier disease onset in Friedreich ataxia ; Delatycki, M. B., Tai, G., Corben, L., Yiu, E. M....
Thursday, January 2, 2014

Molecular and clinical investigation of Iranian patients with friedreich ataxia.

›
Molecular and clinical investigation of Iranian patients with friedreich ataxia. . Salehi MH, Houshmand M, Aryani O, Kamalidehghan B, Khalil...

BIOMARKERS IN RARE NEUROMUSCULAR DISEASES

›
BIOMARKERS IN RARE NEUROMUSCULAR DISEASES . Chiara Scotton, Chiara Passarelli, Marcella Neri, Alessandra Ferlini; Experimental Cell Research...

Agilis Biotherapeutics and Intrexon to Pursue Transformative Therapies for Rare Genetic Disease

›
Agilis Biotherapeutics and Intrexon to Pursue Transformative Therapies for Rare Genetic Disease . NEW YORK and GERMANTOWN, Md., Dec. 31, 201...